Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO.

Détails

Ressource 1Télécharger: Meier_SMW2017_SVGO.pdf (567.86 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_2F7530178F85
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO.
Périodique
Swiss medical weekly
Auteur(s)
Meier C., Uebelhart B., Aubry-Rozier B., Birkhäuser M., Bischoff-Ferrari H.A., Frey D., Kressig R.W., Lamy O., Lippuner K., Stute P., Suhm N., Ferrari S.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
05/09/2017
Peer-reviewed
Oui
Volume
147
Pages
w14484
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density. As first-line treatment most patients are started with an antiresorptive treatment, i.e. drugs that inhibit osteoclast development and/or function (bisphosphonates, denosumab, oestrogens or selective oestrogen receptor modulators). In the balance between benefits and risks of antiresorptive treatment, uncertainties remain regarding the optimal treatment duration and the management of patients after drug discontinuation. Based on the available evidence, this position statement will focus on the long-term management of osteoporosis therapy, formulating decision criteria for clinical practice.
Mots-clé
Antibodies, Monoclonal, Humanized/therapeutic use, Bone Density Conservation Agents/therapeutic use, Denosumab/therapeutic use, Diphosphonates/therapeutic use, Evidence-Based Practice, Female, Humans, Osteoporosis/drug therapy, Osteoporotic Fractures/prevention & control, Risk Factors, Time Factors
Pubmed
Web of science
Open Access
Oui
Création de la notice
28/12/2017 16:15
Dernière modification de la notice
03/02/2020 16:19
Données d'usage